Group Leader - Large Molecule Screening

Req ID:  73713
Location: 

Saffron Walden, GB, CB10 1XL

For 70 years, Charles River employees have worked together to assist in the discovery, development and safe manufacture of new drug therapies. When you join our family, you will have a significant impact on the health and well-being of people across the globe. Whether your background is in life sciences, finance, IT, sales or another area, your skills will play an important role in the work we perform. In return, we’ll help you build a career that you can feel passionate about.

Our expanding large molecule discovery team, based in Saffron Walden, is looking to recruit a Group Leader with experience in large molecule assay design and screening.

 
The ideal candidate will have significant experience in developing assays suitable for large molecule drug discovery, in a range of formats.  You will have experience of running these assays in large molecule discovery projects; ideally, you will also have experience of troubleshooting common assay problems and training others to use these assays. 

 

Key knowledge/skills:

  • Biologic discovery project leadership
  • Understanding of large molecule work-flows, and demonstrable strategic influence on large molecule discovery strategies across a number of target classes, including multi-pass transmembrane proteins
  • Large molecule assay design and validation – for example biochemical receptor/ligand competition assays and reporter cell assays. Experience in the use of higher throughput FACS and kinetic analyses desirable
  • 96/384-well biologic sample preparation and screening – bacterial and mammalian cell culture
  • Informal supervision or coaching of junior staff 

 

Desirable:

  • Phage or yeast display experience
  • In vitro library generation
  • Antibody and antibody fragment expression and purification
  • Antibody and antibody fragment engineering
  • Formal line management experience, including development of more junior staff and performance management experience.

 

About Safety Assessment
Charles River is committed to helping our partners expedite their preclinical drug development with exceptional safety assessment services, state-of-the-art facilities and expert regulatory guidance. From individual specialty toxicology and IND enabling studies to tailored packages and total laboratory support, our deeply experienced team can design and execute programs that anticipate challenges and avoid roadblocks for a smooth, efficient journey to market.  Each year approximately 300 investigational new drug (IND) programs are conducted in our Safety Assessment facilities.

 

About Charles River
Charles River is an early-stage contract research organization (CRO). We have built upon our foundation of laboratory animal medicine and science to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, to support clients from target identification through preclinical development. Charles River also provides a suite of products and services to support our clients’ clinical laboratory testing needs and manufacturing activities. Utilizing this broad portfolio of products and services enables our clients to create a more flexible drug development model, which reduces their costs, enhances their productivity and effectiveness to increase speed to market.

 

With over 17,000 employees within 90 facilities in 20 countries around the globe, we are strategically positioned to coordinate worldwide resources and apply multidisciplinary perspectives in resolving our client’s unique challenges. Our client base includes global pharmaceutical companies, biotechnology companies, government agencies and hospitals and academic institutions around the world. And in 2019, revenue increased  to $2.62 billion.

 

At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guide us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. We have proudly supported the development of ~85% of the drugs approved by the FDA in 2019.